Zogenix, GW Pharma Discovering Epilepsy Treatments
Zogenix is searching for and developing treatments for rare diseases such as those that cause different forms of epilepsy. Just this week, Zogenix received a patent (US Pat. No. 10,603,290) for a treatment for seizures which uses fenfluramine in combination with cannabidiol to counter a metabolism pathway that creates norfenfluramine having undesired side effects. Cannabidiol has been combined with other drugs, such as botox, to downplay some of the side effects of the primary drug.
Zogenix is not alone in the cannabis for epilepsy space. In fact, as you may have already guessed, GW Pharmaceuticals was also listed this week for a grant for patent 10,603,288. Patent ‚Äò288 claims a CBD composition, also in the presence of another epilepsy treating drug, for “treatment-resistant epilepsy”.
GW Pharmaceuticals is the leading patent assignee in the cannabis sector. Take a custom look at the cannabis sector IP landscape at patentforecast.com with a subscription.
Related Posts
Cannabis Popularity Soars Along With Tests To Detect It
The Duquenois Levine Test is used in the field by law enforcement officers to test for THC presence in a suspected sample. The problem with…
Hound Labs, Cannabix and Vox Heat Up the Marijuana Breathalyzer Market
At the start of April 2021, Patent Forecast® released an insight going over some of the big name competitors getting their foot in the door…
Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees
Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…
